Dare Bioscience, Inc. Comprehensive Income
Dare Bioscience, Inc. (DARE) reported Comprehensive Income of -$2.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- Dare Bioscience, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$2.98M.
- Dare Bioscience, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$2.96M.
- Dare Bioscience, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$1.47M.
- Dare Bioscience, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$3.56M.
- Dare Bioscience, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$13.39M.
- Dare Bioscience, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$4.12M.
- Dare Bioscience, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$30.17M.
- Dare Bioscience, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$31.14M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.98M 10-Q · filed 2026-08-13 | -$5.94M 10-Q · filed 2026-08-13 | -$7.40M derived: sum of 3 quarters · filed 2026-08-13 | -$10.96M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$2.96M 10-Q · filed 2026-05-14 | -$4.42M derived: sum of 2 quarters · filed 2026-05-14 | -$7.98M derived: sum of 3 quarters · filed 2026-05-14 | -$11.98M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$5.02M derived: sum of 2 quarters · filed 2026-03-26 | -$9.03M derived: sum of 3 quarters · filed 2026-08-13 | -$13.39M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$3.56M 10-Q · filed 2025-11-13 | -$7.56M derived: sum of 2 quarters · filed 2026-08-13 | -$11.92M 10-Q · filed 2025-11-13 | -$17.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$4.00M 10-Q · filed 2026-08-13 | -$8.37M 10-Q · filed 2026-08-13 | -$13.94M derived: sum of 3 quarters · filed 2026-08-13 | -$18.62M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$4.37M 10-Q · filed 2026-05-14 | -$9.94M derived: sum of 2 quarters · filed 2026-05-14 | -$14.62M derived: sum of 3 quarters · filed 2026-05-14 | -$1.69M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$10.25M derived: sum of 2 quarters · filed 2026-03-26 | $2.67M derived: sum of 3 quarters · filed 2026-03-26 | -$4.12M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$4.68M 10-Q · filed 2025-11-13 | $8.25M derived: sum of 2 quarters · filed 2025-11-13 | $1.45M 10-Q · filed 2025-11-13 | -$3.55M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $12.93M 10-Q · filed 2025-08-14 | $6.13M 10-Q · filed 2025-08-14 | $1.13M derived: sum of 3 quarters · filed 2025-08-14 | -$7.18M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$6.79M 10-Q · filed 2025-05-13 | -$11.79M derived: sum of 2 quarters · filed 2025-05-13 | -$20.11M derived: sum of 3 quarters · filed 2025-05-13 | -$28.90M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$13.31M derived: sum of 2 quarters · filed 2025-03-31 | -$22.11M derived: sum of 3 quarters · filed 2025-03-31 | -$30.17M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$8.31M 10-Q · filed 2024-11-14 | -$17.11M derived: sum of 2 quarters · filed 2024-11-14 | -$25.17M 10-Q · filed 2024-11-14 | -$40.94M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$8.79M 10-Q · filed 2024-08-12 | -$16.86M 10-Q · filed 2024-08-12 | -$32.62M derived: sum of 3 quarters · filed 2024-08-12 | -$39.87M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$8.06M 10-Q · filed 2024-05-14 | -$23.83M derived: sum of 2 quarters · filed 2024-05-14 | -$31.08M derived: sum of 3 quarters · filed 2024-05-14 | -$30.80M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$15.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$23.01M derived: sum of 2 quarters · filed 2024-03-28 | -$22.74M derived: sum of 3 quarters · filed 2024-03-28 | -$31.14M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$7.25M 10-Q · filed 2023-11-09 | -$6.97M derived: sum of 2 quarters · filed 2023-11-09 | -$15.38M 10-Q · filed 2023-11-09 | -$24.91M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $278.13K 10-Q · filed 2023-08-10 | -$8.13M 10-Q · filed 2023-08-10 | -$17.66M derived: sum of 3 quarters · filed 2023-08-10 | -$30.39M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$8.41M 10-Q · filed 2023-05-11 | -$17.93M derived: sum of 2 quarters · filed 2023-05-11 | -$30.67M derived: sum of 3 quarters · filed 2023-05-11 | -$39.84M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$9.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$22.26M derived: sum of 2 quarters · filed 2023-03-30 | -$31.43M derived: sum of 3 quarters · filed 2023-03-30 | -$38.76M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$12.73M 10-Q · filed 2022-11-10 | -$21.90M derived: sum of 2 quarters · filed 2022-11-10 | -$29.23M 10-Q · filed 2022-11-10 | -$37.65M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$9.17M 10-Q · filed 2022-08-09 | -$16.50M 10-Q · filed 2022-08-09 | -$24.92M derived: sum of 3 quarters · filed 2022-08-09 | -$32.51M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$7.33M 10-Q · filed 2022-05-12 | -$15.75M derived: sum of 2 quarters · filed 2022-05-12 | -$23.34M derived: sum of 3 quarters · filed 2022-05-12 | -$30.45M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$8.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$16.01M derived: sum of 2 quarters · filed 2022-03-31 | -$23.12M derived: sum of 3 quarters · filed 2022-03-31 | -$27.40M 10-K · filed 2022-03-31 |
| 2020-09-30 | -$7.59M 10-Q · filed 2021-11-10 | -$14.70M derived: sum of 2 quarters · filed 2021-11-10 | -$18.98M 10-Q · filed 2021-11-10 | -$22.83M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$7.11M 10-Q · filed 2021-08-12 | -$11.39M 10-Q · filed 2021-08-12 | -$15.24M derived: sum of 3 quarters · filed 2021-08-12 | -$18.65M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$4.28M 10-Q · filed 2021-05-13 | -$8.13M derived: sum of 2 quarters · filed 2021-05-13 | -$11.54M derived: sum of 3 quarters · filed 2021-05-13 | -$16.29M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | -$7.27M derived: sum of 2 quarters · filed 2021-03-30 | -$12.02M derived: sum of 3 quarters · filed 2021-03-30 | -$15.06M 10-K · filed 2021-03-30 |
| 2019-09-30 | -$3.41M 10-Q · filed 2020-11-12 | -$8.16M derived: sum of 2 quarters · filed 2020-11-12 | -$11.20M 10-Q · filed 2020-11-12 | -$14.14M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | -$4.75M 10-Q · filed 2020-08-12 | -$7.79M 10-Q · filed 2020-08-12 | -$10.73M derived: sum of 3 quarters · filed 2020-08-12 | -$13.32M derived: sum of 4 quarters · filed 2020-08-12 |
| 2019-03-31 | -$3.04M 10-Q · filed 2020-05-14 | -$5.98M derived: sum of 2 quarters · filed 2020-05-14 | -$8.57M derived: sum of 3 quarters · filed 2020-05-14 | -$12.18M derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | -$2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | -$5.53M derived: sum of 2 quarters · filed 2020-03-27 | -$9.14M derived: sum of 3 quarters · filed 2020-03-27 | -$16.82M 10-K · filed 2020-03-27 |
| 2018-09-30 | -$2.59M 10-Q · filed 2019-11-12 | -$6.20M derived: sum of 2 quarters · filed 2019-11-12 | -$13.88M 10-Q · filed 2019-11-12 | -$23.02M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | -$3.61M 10-Q · filed 2019-08-14 | -$11.29M 10-Q · filed 2019-08-14 | -$20.43M derived: sum of 3 quarters · filed 2019-08-14 | -$22.07M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | -$7.68M 10-Q · filed 2019-05-14 | -$16.82M derived: sum of 2 quarters · filed 2019-05-14 | -$18.46M derived: sum of 3 quarters · filed 2019-05-14 | -$18.96M derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | -$9.14M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | -$10.78M derived: sum of 2 quarters · filed 2019-04-01 | -$11.28M derived: sum of 3 quarters · filed 2019-04-01 | -$11.52M 10-K · filed 2019-04-01 |
| 2017-09-30 | -$1.64M 10-Q · filed 2018-11-13 | -$2.14M derived: sum of 2 quarters · filed 2018-11-13 | -$2.38M 10-Q · filed 2018-11-13 | -$2.58M derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | -$498.19K 10-Q · filed 2018-08-13 | -$742.06K 10-Q · filed 2018-08-13 | -$942.59K derived: sum of 3 quarters · filed 2018-08-13 | -$958.69K derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-03-31 | -$243.86K 10-Q · filed 2018-05-14 | -$444.40K derived: sum of 2 quarters · filed 2018-05-14 | -$460.50K derived: sum of 3 quarters · filed 2018-05-14 | |
| 2016-12-31 | -$200.53K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28 | -$216.64K derived: sum of 2 quarters · filed 2018-03-28 | -$672.69K 10-K · filed 2018-03-28 | |
| 2016-09-30 | -$16.11K 10-Q · filed 2017-11-13 | -$472.15K 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |